E2F3 and neuroblastoma: E2F3 expression levels were higher in MYCN amplified neuroblastoma patients in TARGET, GSE16476, GSE85047 and E-MTAB-1781 datasets, compared with neuroblastoma patients without MYCN amplification (Fig. 4b).